Trial
NCT04406857
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Locally Advanced Rectal Carcinoma
Intervention
Capecitabine
Why stopped
Inadequate accrual rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-26